Why Mexidol®?

Time codes:
  • 01:02

    History of the drug Mexidol®

  • 01:40

    The mechanism of action of the drug Mexidol®

  • 03:03

    Mexidol® - pharmacological effects

  • 03:54

    Clinical effects and safety of Mexidol®

  • 04:30

    Security Profile

  • 05:09

    The optimal dose and duration of intravenous infusion and intramuscular injection

  • 05:50

    Mexol 125 mg, Mexidol® Fort 250 mg transition

  • 06:20

    Evidence base of the effectiveness of Mexidol

  • 06:45

    The results of the study of Epic

  • 08:16

    Clinical recommendations

  • 09:40

    Differences in Mexidol® and analogues.

Schukin Ivan Aleksandrovich - Ph.D., Associate Professor of the Department of Neurology, Neurosurgery and Medical Genetics LF RNIMU named after N.I. Pirogov

Announcement:

Schukin Ivan Alexandrovich - candidate of medical sciences, associate professor of the Department of Neurology of the Russian State Medical University, answers the main questions about the drug Mexol®. Why is Mexidol® so widely prescribed and popular among doctors and patients? What pharmacological and clinical effects does it have? What is the evidence base and methods of using the drug Mexidol®? Let's figure it out!

Block of articles on this topic

Mexidol: a spectrum of pharmacological effects

Author:
T.A. Voronin

Nii pharmacology named after V.V. Zakusov RAMS, Moscow

Original and reproduced drugs: what do the clinician need to know?

Author:
A.V. Schulkin, A.A. Filimonova
FSBEI in the Ryazan State Medical University of the Ministry of Health of Russia, Ryazan, Russia

Personal: To the question of evidence -based neuroprotective therapy: Focus on ethylmethylhydroxypyridine succinate

Authors:
A.I. Kochetkov, N.A. Shatalova, M.V. Klepikova, T.V. Filippova, O.D. Ostroumova

FSBEA DPO “Russian Medical Academy of Continuing Professional Education” of the Ministry of Health of Russia, Moscow

The results of a randomized double blind multicenter placebo-controlled in parallel groups of the study and safety of Mexidol with prolonged consistent therapy in patients in the acute and early recovery periods
Personal: the results of an international multicenter randomized double-blind-controlled study of evaluating the effectiveness of the effectiveness and safety of sequential therapy of patients with chronic brain ischemia with Mexidol and Mexidol Forte 250 (study of Memo)

Authors:
A.I. Fedin 1 , V.V. Zakharov 2 , M.M. Tanashian 3 , E.I. Chukanova 1 , E.N. Majidova 4 , L.A. Shchepankevich 5.6 , O.D. Ostroumova 7

THE INFORMATION IS INTENDED FOR HEALTHCARE AND PHARMACEUTICAL PROFESSIONALS. THIS INFORMATION IS NOT INTENDED AS A SUBSTITUTE FOR MEDICAL ADVICE.

Source of photos and images Shutterstock.com